Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Research & Development (2023 - 2025)

Historic Research & Development for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $49.2 million.

  • Immunome's Research & Development rose 3223.92% to $49.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.4 million, marking a year-over-year increase of 9104.82%. This contributed to the annual value of $129.5 million for FY2024, which is 46105.5% up from last year.
  • Latest data reveals that Immunome reported Research & Development of $49.2 million as of Q3 2025, which was up 3223.92% from $40.5 million recorded in Q2 2025.
  • Immunome's 5-year Research & Development high stood at $49.2 million for Q3 2025, and its period low was $3.8 million during Q3 2023.
  • Over the past 3 years, Immunome's median Research & Development value was $29.1 million (recorded in 2024), while the average stood at $25.4 million.
  • As far as peak fluctuations go, Immunome's Research & Development surged by 87305.78% in 2024, and later surged by 3223.92% in 2025.
  • Immunome's Research & Development (Quarter) stood at $9.6 million in 2023, then surged by 396.94% to $47.9 million in 2024, then increased by 2.72% to $49.2 million in 2025.
  • Its Research & Development stands at $49.2 million for Q3 2025, versus $40.5 million for Q2 2025 and $36.9 million for Q1 2025.